In a phase 3 clinical trial, mean cutaneous safety
and tolerability scores (range 0-3) were generally mild at 12 weeks2,3
Severe 3
Moderate 2
Mild 1
Cutaneous Safety Evaluations
Tolerability Evaluations (Patient Reported)
- Onexton
- Vehicle
- At Week 12, no more than 2% of patients studied showed moderate local skin reactions, and fewer than 1% showed severe reactions2
- Some skin reactions increased during treatment, peaked around Week 4, and returned to baseline or improved by Week 122